# Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg

> **NCT00242775** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2100 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/formoterol Turbuhaler
- **DRUG:** Salmeterol/fluticasone Diskus

## Key facts

- **NCT ID:** NCT00242775
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 2100 (—)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242775, "Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00242775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*